Peritoneal Dialysis Market Expected to Reach US$ 21.55 Billion by 2034 | The Insight Partners

The Insight Partners forecasts the global peritoneal dialysis market to grow from US$11.56B in 2025 to US$21.55B by 2034 (7.4% CAGR, 2026–2034), driven by rising CKD/ESRD and a shift toward home-based care. Growth is expected to be supported by connected/remote monitoring platforms and automated peritoneal dialysis (APD) adoption. Recent industry developments include Fresenius Medical Care’s global Kinexus launch (June 2026) and Vantive’s HomeAdvantage ecosystem launch (Nov 2025).

Analysis

The investable signal is not the market-size growth itself; it is the migration of economic value from in-center procedures to a recurring, logistics-heavy home-care stack. That usually favors integrated operators with patient onboarding, supply fulfillment, and remote monitoring, while pure product vendors face faster commoditization unless they control the software or the catheter/access point. For DVA, the upside is modest but real if home therapy improves retention and lowers abandoned starts; if not, the economics just add more service burden without enough incremental margin.

BAX is the clearest example of the market misreading the read-through. The higher-growth kidney-care story now sits mostly outside the public equity, so a multiple rerate in the legacy ticker would be more sentiment than fundamentals. The more interesting second-order effect is competitive pressure on smaller renal suppliers: the winner is whoever can bundle consumables, digital adherence, and last-mile delivery, which can squeeze standalone device ASPs and make APAC growth look volume-rich but margin-poor.

The contrarian risk is that the home-dialysis narrative is operationally fragile. If infection, technique failure, or patient burnout keep switch-out rates elevated, the next 1-3 quarters may bring tighter payer scrutiny rather than faster adoption, and the 6-18 month outcome would be a slower, more incremental mix shift than bulls expect. The key falsifier is any deterioration in retention or a flat line in home-start conversion despite all the digital-platform launches.

Key Decisions for Investors

• Small tactical long DVA on pullbacks only if upcoming commentary confirms better home-dialysis starts and retention; use a 3-6 month horizon and exit if transfer-out rates or complication commentary worsen.
• Fade any knee-jerk rally in BAX tied to 'renal care growth' headlines; the direct public-equity lever is weak now that the higher-growth kidney-care asset has been carved out. Treat >3-5% event-driven spikes as opportunities to sell into strength.
• No aggressive position in MDT or smaller renal-device names on this report alone; they are second-order beneficiaries unless management proves recurring pull-through from catheter/access or monitoring attach rates.
• Watch DVA and payer commentary next quarter for home-therapy mix and supply-order cadence; if home penetration stalls while the industry keeps emphasizing growth, the right trade becomes a defensive one, not a cyclical growth long.